TNG — Transgene SA Share Price
Last trade - 00:00- €140.77m
- €142.40m
- €7.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.02 | ||
| Price to Tang. Book | 9.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.44 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.42% | ||
| Return on Equity | -83.54% | ||
| Operating Margin | -393.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 13.3 | 9.34 | 17.01 | 10 | 7.63 | 31.5 | 95 | 1.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Directors
- Hedi Brahim CHM (40)
- Christophe Ancel DCE (57)
- Jean-Philippe Del CFO (41)
- Eric Quemeneur EVP (57)
- John Felitti GCN (51)
- Gaelle Stadtler DHR (37)
- Maud Brandely MGB (67)
- Thibaut du Fayet MGB (53)
- Philippe Archinard DRC (62)
- Sandrine Flory DRC (51)
- Jean-Luc Belingard NED (72)
- Antoine Beret NID (76)
- Jean-Pierre Bizzari NID (66)
- Benoit Habert NID (57)
- Marie-Yvonne Landel NID (68)
- Maya Said NID (44)
- Laurence Zitvogel NID (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 1979
- Public Since
- March 25th, 1998
- No. of Employees
- 164
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 100,548,881
- Address
- 400 Boulevard Gonthier d'Andernach, ILLKIRCH-GRAFFENSTADEN, 67405
- Web
- https://www.transgene.fr
- Phone
- +33 388279100
- Contact
- Lucie Larguier
- Auditors
- KPMG S.A.
Latest News for TNG
Upcoming Events for TNG
Transgene SA at Van Lanschot Kempen Life Sciences Conference
Q1 2024 Transgene SA Earnings Release
Transgene SA Annual Shareholders Meeting
Transgene SA at Oddo BHF Nextcap Forum (Virtual)
Half Year 2024 Transgene SA Earnings Release
Similar to TNG
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 19:22 UTC, shares in Transgene SA are trading at €1.40. This share price information is delayed by 15 minutes.
Shares in Transgene SA last closed at €1.40 and the price had moved by -27.08% over the past 365 days. In terms of relative price strength the Transgene SA share price has underperformed the FTSE Global All Cap Index by -32.74% over the past year.
The overall consensus recommendation for Transgene SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Transgene SA does not currently pay a dividend.
Transgene SA does not currently pay a dividend.
Transgene SA does not currently pay a dividend.
To buy shares in Transgene SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.40, shares in Transgene SA had a market capitalisation of €140.77m.
Here are the trading details for Transgene SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: TNG
Based on an overall assessment of its quality, value and momentum Transgene SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Transgene SA is €4.50. That is 221.43% above the last closing price of €1.40.
Analysts covering Transgene SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.34 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Transgene SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -11.93%.
As of the last closing price of €1.40, shares in Transgene SA were trading -4.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Transgene SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Transgene SA's management team is headed by:
- Hedi Brahim - CHM
- Christophe Ancel - DCE
- Jean-Philippe Del - CFO
- Eric Quemeneur - EVP
- John Felitti - GCN
- Gaelle Stadtler - DHR
- Maud Brandely - MGB
- Thibaut du Fayet - MGB
- Philippe Archinard - DRC
- Sandrine Flory - DRC
- Jean-Luc Belingard - NED
- Antoine Beret - NID
- Jean-Pierre Bizzari - NID
- Benoit Habert - NID
- Marie-Yvonne Landel - NID
- Maya Said - NID
- Laurence Zitvogel - NID